Development of pulmonary infiltrates with respiratory symptoms in patients with advanced cancer presents a diagnostic challenge. We describe a case of a patient who developed progressive respiratory failure and bilateral lung infiltrates whilst receiving docetaxel chemotherapy for advanced lung cancer. After excluding other aetiologies, he was treated for docetaxel-related pneumonitis with corticosteroid therapy. Interstitial pneumonitis is a rare complication of Docetaxel chemotherapy but needs to be recognised and treated early, as it is associated with high mortality rates. We describe the presentation, differential diagnoses and possible mechanisms associated with drug-related pneumonitis
Pneumonitis is a rare but serious complication associated with paclitaxel and/or trastuzumab treatme...
A 69-year-old man with castration-resistant prostate cancer (CRPC) received docetaxel and a corticos...
OBJECTIVE:Combination treatment with ramucirumab and paclitaxel shows significant efficacy in patien...
Background: Pulmonary toxicity is a well-known complication observed with several anticancer drugs. ...
Pneumonitis is a rare but serious complication of docetaxel treatment. We report a 63-year-old woman...
Incidence of diffuse alveolar damage is rarely seen after administration of docetaxel used alone or ...
Abstract Taxane‐induced pneumotoxicity is rare. However, 1–5% of patients taking docetaxel may devel...
Docetaxel has proven effective in many solid tumors, including breast cancer. Hypersensitivity react...
Interstitial lung disease associated with docetaxel in a patient treated for breast cancer — a case ...
Docetaxel is a semisynthetic cytostatic drug that belongs to the family of taxoids. Docetaxel inhibi...
Docetaxel belongs to the taxane family of anti-cancer drugs, which are commonly used in non-small ce...
Interstitial lung disease (ILD) is a collective term for a group of disorders that result in inflamm...
OBJECIlVE: To reportthree cases of paclitaxel-induced acutebilateral pneumonitis, as wellas to ascer...
  Docetaxel belongs to taxane family of antineoplastic agents that are indicated for the treatment...
Gemcitabine and docetaxel combination chemotherapy is the standard of care for patients with unresec...
Pneumonitis is a rare but serious complication associated with paclitaxel and/or trastuzumab treatme...
A 69-year-old man with castration-resistant prostate cancer (CRPC) received docetaxel and a corticos...
OBJECTIVE:Combination treatment with ramucirumab and paclitaxel shows significant efficacy in patien...
Background: Pulmonary toxicity is a well-known complication observed with several anticancer drugs. ...
Pneumonitis is a rare but serious complication of docetaxel treatment. We report a 63-year-old woman...
Incidence of diffuse alveolar damage is rarely seen after administration of docetaxel used alone or ...
Abstract Taxane‐induced pneumotoxicity is rare. However, 1–5% of patients taking docetaxel may devel...
Docetaxel has proven effective in many solid tumors, including breast cancer. Hypersensitivity react...
Interstitial lung disease associated with docetaxel in a patient treated for breast cancer — a case ...
Docetaxel is a semisynthetic cytostatic drug that belongs to the family of taxoids. Docetaxel inhibi...
Docetaxel belongs to the taxane family of anti-cancer drugs, which are commonly used in non-small ce...
Interstitial lung disease (ILD) is a collective term for a group of disorders that result in inflamm...
OBJECIlVE: To reportthree cases of paclitaxel-induced acutebilateral pneumonitis, as wellas to ascer...
  Docetaxel belongs to taxane family of antineoplastic agents that are indicated for the treatment...
Gemcitabine and docetaxel combination chemotherapy is the standard of care for patients with unresec...
Pneumonitis is a rare but serious complication associated with paclitaxel and/or trastuzumab treatme...
A 69-year-old man with castration-resistant prostate cancer (CRPC) received docetaxel and a corticos...
OBJECTIVE:Combination treatment with ramucirumab and paclitaxel shows significant efficacy in patien...